Generics and Biosimilars Initiative (GaBI), founded by Professor Huub Schellekens, Professor Arnold G Vulto, both from The Netherlands; and Ms Lasia Tang from Belgium; aims to foster the worldwide efficient use of high-quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable healthcare.

The objective of GaBI is to raise the scientific status of generic and biosimilar medicines, via well-documented and up-to-date information about generic and biosimilar medicines both in print and electronically (www.gabionline.net) in an open access format, providing high-quality, scientifically sound and reliable information to healthcare professionals including physicians, pharmacists and nurses, consumers, drug developers, third party payers, legislators and assessors; who are in need of a reliable, critical and independent source of information on all aspects of generic and biosimilar medicines.

GaBI's mission - building trust in cost-effective treatments.
Ltang@gabionline.net - www.gabionline.net

Generics bulletin is the global generic industry’s essential source of news and views on product launches, company deals, regulatory changes and patent pricing and reimbursement issues. Two formats: a weekly electronic newsflash and a twice-monthly paper publication provide both immediacy and depth from a generics industry perspective. For further information please visit www.generics-bulletin.com or contact Val Davis at val.davis@generics-bulletin.com or call +44 (0)1564 777550.

Journal of Generic Medicines is the global authoritative source for original insight and analysis of the generic medicines sector and is guided by an international board of senior executives, association presidents, public service officials and leading academics. Visit the website at www.palgrave-journals.com/jgm to find out more.

PharmaVOICE magazine, reaching more than 17,500 U.S.-based life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE, and its supporting VIEW publications, provide readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts. Additionally, PharmaVOICEMarketplace.com provides a comprehensive directory of products, services, and solutions for the life-sciences industry. To Raise Your VOICE, contact feedback@pharmavoice.com.

Pharmawire publishes real-time news and data on the most price sensitive issues in the global pharmaceutical market. Built for financial professionals, Pharmawire covers product approvals, litigation, licensing deals and M&A. Pharmawire is a part of The Mergermarket Group, a division of the Financial Times Group, publisher of the Financial Times newspaper and FT.com. The FT Group is a division of Pearson plc, the international media group.

Player or investor, lawyer or contractor, if you need to know pharma, you need to know ScripWorld Pharmaceutical News. Most people in the industry do. We've been the leading provider of global pharmaceutical news for over thirty years.

Thomson Reuters is a leading source of intelligent information for hedge funds and their investors, powered by the world's most trusted news organization. We combine value-added content, transactions and innovative technology to deliver workflows for analysts, investment managers and traders, as well as solutions for quantitative research, high frequency trading and risk management.